InvestorsHub Logo
Followers 266
Posts 52491
Boards Moderated 8
Alias Born 08/29/2007

Re: I-Glow post# 139633

Monday, 05/14/2018 12:43:17 PM

Monday, May 14, 2018 12:43:17 PM

Post# of 203914
From the National Cancer Institute website:

Summary of the Evidence for Cannabis and Cannabinoids
To assist readers in evaluating the results of human studies of integrative, alternative, and complementary therapies for people with cancer, the strength of the evidence (i.e., the levels of evidence) associated with each type of treatment is provided whenever possible. To qualify for a level of evidence analysis, a study must:

Be published in a peer-reviewed scientific journal.
Report on therapeutic outcome or outcomes, such as tumor response, improvement in survival, or measured improvement in quality of life.
Describe clinical findings in sufficient detail for a meaningful evaluation to be made.
Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., endpoints) measured. The resulting two scores are then combined to produce an overall score. An overall level of evidence score cannot be assigned to cannabinoids because there has been insufficient clinical research to date. For an explanation of possible scores and additional information about levels of evidence analysis of CAM treatments for people with cancer, refer to Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies.

The Nasdaq's third tier, the AMEX can be just as bad, and last but not least, the OTC, it seems, are financial venues that reward failure.